Advertisement

Advances in Therapy

, Volume 24, Issue 2, pp 333–345 | Cite as

Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis

  • Lisa LundquistEmail author
Article

Abstract

An enhanced understanding of the immunopathology of rheumatoid arthritis (RA) has led to the development of novel therapies that target specific events occurring in the immune cascade that underlies the disease. In December 2005, abatacept became the first therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with moderately to severely active RA who have exhibited an inadequate response to traditional disease-modifying antirheumatic drugs or tumor necrosis factor antagonists. This article summarizes the characteristics and clinical profile of abatacept. Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation. It is indicated for reducing signs and symptoms of the disorder, inducing a major clinical response, slowing the progression of structural damage, and improving physical function in this patient population. Data on abatacept compiled to date demonstrate significant efficacy, combined with a consistent safety profile and tolerability, in a wide range of patients with RA, including those with an inadequate response to methotrexate or to tumor necrosis factor antagonists.

Keywords

abatacept T cells co-stimulation rheumatoid arthritis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lee DM, Weinblatt ME. Rheumatoid arthritis.Lancet. 2001; 358: 903–911.PubMedCrossRefGoogle Scholar
  2. 2.
    Genentech. Rituxan® (rituximab) prescribing information. Available at: www.rituxan.com. Accessed August 3, 2006.Google Scholar
  3. 3.
    Bristol-Myers Squibb. Orencia® (abatacept) prescribing information. Available at: www.orencia.com. Accessed August 3, 2006.Google Scholar
  4. 4.
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis.N Engl J Med. 2001; 344: 907–916.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation.J Am Soc Nephrol. 2002; 13: 559–575.PubMedGoogle Scholar
  6. 6.
    Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis.J Clin Rheumatol. 2005; 11(3 suppl): S55-S62.PubMedCrossRefGoogle Scholar
  7. 7.
    Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.Arthritis Rheum. 2002; 46: 1470–1479.PubMedCrossRefGoogle Scholar
  8. 8.
    Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.N Engl J Med. 2003; 349: 1907–1915.PubMedCrossRefGoogle Scholar
  9. 9.
    Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial.Arthritis Rheum. 2005; 52: 2263–2271.PubMedCrossRefGoogle Scholar
  10. 10.
    Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.Ann Rheum Dis. 2007; 66: 228–234.PubMedCrossRefGoogle Scholar
  11. 11.
    Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.Ann Intern Med. 2006; 144: 865–876.PubMedGoogle Scholar
  12. 12.
    Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.N Engl J Med. 2005; 353: 1114–1123.PubMedCrossRefGoogle Scholar
  13. 13.
    Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a 1 year randomized, placebo-controlled study.Arthritis Rheum. 2006; 54: 2807–2816.PubMedCrossRefGoogle Scholar
  14. 14.
    Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.Arthritis Rheum. 2004; 50: 1412–1419.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2007

Authors and Affiliations

  1. 1.Mercer University College of Pharmacy and Health ScienceAtlanta

Personalised recommendations